Back to Stocks

RAPP

Rapport Therapeutics, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Rapport Therapeutics has fundamentally shifted its financial trajectory through a strategic $20 million upfront collaboration with Tenacia Biotechnology.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the appearance of a 'cash-rich' balance sheet, Rapport Therapeutics continues to face a daunting burn rate, with a net loss of $19.9 million in Q1 2026 even after accounting for the one-time Tenacia fee.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every RAPP filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company at a critical juncture, balancing a fortress balance sheet against the immense capital demands of late-stage clinical trials. The Tenacia collaboration is a clear strategic win, providing both capital and geographic diversification. However, the financial statements highlight a growing appetite for R&D spend, which rose 67% year-over-year to $32.7 million as the company prepares for Phase 3 launches. Ultimately, the investment thesis hinges on the binary outcomes of the RAP-219 trials. If the upcoming Phase 3 initiations and bipolar mania data are positive, the current cash position provides a sufficient bridge to commercialization. Conversely, the 'hidden' obligations to partners like Janssen and the inherent unpredictability of the FDA approval process mean that the current liquidity is not a guarantee of safety, but rather a window of opportunity for the company to prove its clinical hypothesis.

Selected Quarter

Core Takeaway

Rapport has successfully shifted from a pure discovery play to a catalyst-driven developer, but high Phase 3 costs threaten the 'no-dilution' narrative.

Investor Lens

The trade-off between current balance sheet strength and the high-risk, high-cost nature of late-stage neurology trials.

Watch Next

Topline data for bipolar mania expected in Q4 2026 and Phase 3 initiation in Q2 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.03Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Secured $20M upfront non-dilutive payment from Tenacia collaboration.

capital raise
70%
bearishMay 7

Operating expenses rose 62% YoY to $44.2M due to clinical trial scaling.

margin compression
60%
neutralMay 7

Net loss of $19.9M despite one-time revenue infusion.

earnings miss
40%
bullishMay 7

Secured $20M upfront non-dilutive payment from Tenacia collaboration.

capital raise
70%
bearishMay 7

Operating expenses rose 62% YoY to $44.2M due to clinical trial scaling.

margin compression
60%
neutralMay 7

Net loss of $19.9M despite one-time revenue infusion.

earnings miss
40%
bullishMay 7

Secured $20M upfront non-dilutive payment from Tenacia collaboration.

capital raise
70%
bearishMay 7

Operating expenses rose 62% YoY to $44.2M due to clinical trial scaling.

margin compression
60%
neutralMay 7

Net loss of $19.9M despite one-time revenue infusion.

earnings miss
40%
bullishMay 7

Secured $20M upfront non-dilutive payment from Tenacia collaboration.

capital raise
70%
bearishMay 7

Operating expenses rose 62% YoY to $44.2M due to clinical trial scaling.

margin compression
60%
neutralMay 7

Net loss of $19.9M despite one-time revenue infusion.

earnings miss
40%
bullishMay 7

Secured $20M upfront non-dilutive payment from Tenacia collaboration.

capital raise
70%
bearishMay 7

Operating expenses rose 62% YoY to $44.2M due to clinical trial scaling.

margin compression
60%
neutralMay 7

Net loss of $19.9M despite one-time revenue infusion.

earnings miss
40%
bullishMay 7

Secured $20M upfront non-dilutive payment from Tenacia collaboration.

capital raise
70%
bearishMay 7

Operating expenses rose 62% YoY to $44.2M due to clinical trial scaling.

margin compression
60%
neutralMay 7

Net loss of $19.9M despite one-time revenue infusion.

earnings miss
40%
bullishMay 7

Secured $20M upfront non-dilutive payment from Tenacia collaboration.

capital raise
70%
bearishMay 7

Operating expenses rose 62% YoY to $44.2M due to clinical trial scaling.

margin compression
60%
neutralMay 7

Net loss of $19.9M despite one-time revenue infusion.

earnings miss
40%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing reveals a company at a critical juncture, balancing a fortress balance sheet against the immense capital demands of late-stage clinical trials. The Tenacia collaboration is a clear strategic win, providing both capital and geographic diversification. However, the financial statements highlight a growing appetite for R&D spend, which rose 67% year-over-year to $32.7 million as the company prepares for Phase 3 launches. Ultimately, the investment thesis hinges on the binary outcomes of the RAP-219 trials. If the upcoming Phase 3 initiations and bipolar mania data are positive, the current cash position provides a sufficient bridge to commercialization. Conversely, the 'hidden' obligations to partners like Janssen and the inherent unpredictability of the FDA approval process mean that the current liquidity is not a guarantee of safety, but rather a window of opportunity for the company to prove its clinical hypothesis.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.